CA
TELO icon

Clearstead Advisors’s Telomir Pharmaceuticals TELO Stock Holding History

Clearstead Advisors’s Portfolio TELO Stock Details TELO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.3K Hold
12,530
– – ﹤0.01% 1492
2025
Q4 		$16.7K Hold
12,530
– – ﹤0.01% 1764
2025
Q3 		$17.4K Buy
+12,530
New +$18.9K ﹤0.01% 1708

Other funds holding TELO

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
SEM
Suncoast Equity Management Tampa, Florida $833M AUM 11.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
WIA
World Investment Advisors Santa Barbara, California $6.2B AUM 19.68% 1-Year Est. Return

Clearstead Advisors's TELO Position: Q1 2026 in Review

Clearstead Advisors held its Telomir Pharmaceuticals (TELO) position steady in Q1 2026 at 12,530 shares worth $16.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1492.

Clearstead Advisors first reported a position in TELO in Q3 2025 and has held it in 3 quarters since. The position peaked at $17.4K in Q3 2025. 27 funds tracked by Wall St. Rank hold TELO as of Q1 2026.

  • Clearstead Advisors held 12,530 shares of Telomir Pharmaceuticals worth $16.3K as of Q1 2026.
  • Clearstead Advisors left its Telomir Pharmaceuticals share count unchanged in Q1 2026.
  • Telomir Pharmaceuticals made up ﹤0.01% of Clearstead Advisors's portfolio in Q1 2026, its #1492 holding.
  • Clearstead Advisors first reported a position in Telomir Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Clearstead Advisors's Telomir Pharmaceuticals position peaked at $17.4K in Q3 2025.
  • 27 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q1 2026.

Based on Clearstead Advisors's 13F filing for Q1 2026, filed 6 May 2026.